Mandy A C Jongeneelen

Title: The Innovations of Mandy A C Jongeneelen

Introduction

Mandy A C Jongeneelen is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of virology, particularly in the development of binding molecules that target influenza viruses. His work has the potential to impact the diagnosis and treatment of influenza infections.

Latest Patents

Mandy Jongeneelen holds a patent for "Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof." This patent describes binding molecules, such as human monoclonal antibodies, that effectively bind to the influenza virus, specifically the H3 subtype, including H3N2. These binding molecules exhibit broad neutralizing activity against the influenza virus. The patent also details polynucleotides encoding these binding molecules, their sequences, and compositions. The binding molecules can be utilized in the diagnosis, prophylaxis, and treatment of H3N2 influenza virus infections. Furthermore, they may provide cross-subtype protection, potentially preventing and treating infections caused by H3, H7, and H10-based influenza subtypes.

Career Highlights

Mandy Jongeneelen is associated with Crucell Holland B.V., where he continues to advance his research and innovations. His work has garnered attention for its potential applications in public health and disease prevention.

Collaborations

Mandy collaborates with esteemed colleagues, including Mark Throsby and Robert H E Friesen, who contribute to his research endeavors and enhance the impact of his innovations.

Conclusion

Mandy A C Jongeneelen's contributions to the field of virology through his innovative binding molecules represent a significant advancement in the fight against influenza viruses. His work not only addresses current health challenges but also paves the way for future research and development in this critical area.